A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
Key facts
- Who runs it
- Peking Union Medical College Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 198 people, planned
- Started
- 7 Jul 2025
- Expected to end
- 20 Aug 2028
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- 5mg lenalidomide
- 10mg lenalidomide
- Prednisone monotherapy
- Record updated
- 30 December 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Patients aged between 18 and 75 years who meet the 2019 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for IgG4-RD;
- Patients with active disease: For patients with initial treatment or relapse after drug withdrawal, active disease is defined as having an IgG4-RD Response Index (RI) of at least 2 points in at least one organ at the time of screening; for those experiencing relapse while on treatment, active disease is defined as having an IgG4-RD RI of at least 3 points in at least one organ at the time of screening;
- Patients with the clinical subtype of proliferative IgG4-RD;
- Patients who have no plans for pregnancy within the next 18 months and who agree to use reliable contraceptive measures during the study period;
Who cannot take part
- Chronic active infection requiring systemic treatment
- Diagnosed with malignant tumor in the past five years
- Patients with a history of thrombosis
- Known to be allergic to lenalidomide or thalidomide
- Patients with any other medical conditions or for specific reasons judged by the investigator to be ineligible to participate in the study
- Absolute neutrophil count <1.5×10\^9 /L or platelet count <100×10\^9/L
- Creatinine clearance less than 60 ml/ min
- IgG4-RD patients with only fibrotic features
- Liver function Child-Pugh grade B or above
- Using biological agents within six months
- Pregnant or lactating women
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
For patients with active proliferative IgG4-RD, we plan to conduct a 52-week prospective randomized controlled trial to compare the efficacy and safety of 5mg lenalidomide plus prednisone, 10mg lenalidomide plus prednisone, and prednisone alone, so as to find new treatment measures for patients with proliferative IgG4-RD.
The 3 groups in the trial
- 5mg lenalidomide groupTreatment being tested
Lenalidomide 5mg/d combined with prednisone, prednisone at an initial dose of 0.6-0.8mg/kg/d for 2-4 weeks, then reduced by 5mg every 1-2 weeks until discontinued (within 24 weeks)
Treatment: 5mg lenalidomide
- 10 mg lenalidomide groupTreatment being tested
Lenalidomide 10mg/ day combined with prednisone, the initial dose of prednisone was 0.6-0.8mg/kg/ day for 2-4 weeks, then 5mg every 1-2 weeks until withdrawal (within 24 weeks).
Treatment: 10mg lenalidomide
- Prednisone monotherapy groupExisting treatment, for comparison
The initial dose of prednisone was 0.6-0.8mg/kg/ day for 2-4 weeks, followed by 5mg every 1-2 weeks until withdrawal (within 24 weeks).
Treatment: Prednisone monotherapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-RD
- Criteria questions
- Built from NCT07068165, who can take part
- Record updated
- 30 December 2025